Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 7/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3396559 | 1.00 | GRIN1 (0.47) | GRIN1GRIN2BHRH3USP2MAPT | |
| SCHEMBL3394954 | 1.00 | GRIN1 (0.47) | GRIN1GRIN2BHRH3USP2MAPT | |
| SCHEMBL8294734 | 0.80 | MAPKAPK2 (0.53) | GRIN1GRIN2BHRH3 | |
| SCHEMBL3396567 | 0.79 | HTR2C (0.57) | GRIN1GRIN2BHTR2AHTR2C | |
| SCHEMBL10962593 | 0.79 | SLC22A1 (0.62) | — | |
| SCHEMBL14781513 | 0.79 | HRH3 (0.47) | GRIN1GRIN2BHRH3 | |
| SCHEMBL7121558 | 0.78 | MAPKAPK2 (0.51) | GRIN1GRIN2B | |
| SCHEMBL4940545 | 0.78 | HTR2C (0.67) | HRH3HTR2AHTR2C | |
| SCHEMBL28314190 | 0.78 | MAOA (0.49) | GRIN1GRIN2BHRH3 | |
| SCHEMBL3394842 | 0.78 | GRIN1 (0.54) | GRIN1GRIN2BHRH3USP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180250308-A1 | NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | WESTFALISCHE WILHELMS-UNIVERSITAT MUNSTER (DE) | 2018-09-06 | — | — | US | disclosed |
| EP-2246331-A1 | NR2B-selective NMDA-receptor antagonists | Westfälische Wilhelms-Universität Münster (DE) | 2010-11-03 | — | — | EP | disclosed |
| EP-2246331-A1 | NR2B-selective NMDA-receptor antagonists | Westfälische Wilhelms-Universität Münster (DE) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010122134-A1 | NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS | Westfälische Wilhelms Universität Münster (DE) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180250308-A1 | NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | GRIN1, GRIN2B, GRIN3B | GRIN1 1/4885GRIN2B 2/4885HRH3 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.